Build Your Comparison

Side-by-side financial analysis
NAKA logo
NAKA
TALK logo
TALK
OPRX logo
OPRX
DOCS logo
DOCS
VEEV logo
VEEV
JPM logo
JPM
Try popular comparisons:

Stock Comparison

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NAKA
Nakamoto Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$74M
5Y Perf.-96.5%
TALK
Talkspace, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$871M
5Y Perf.+98.5%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$95M
5Y Perf.-57.9%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$3.82B
5Y Perf.-26.3%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$25.15B
5Y Perf.-11.1%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$931.59B
5Y Perf.+64.6%

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NAKA logoNAKA
TALK logoTALK
OPRX logoOPRX
DOCS logoDOCS
VEEV logoVEEV
JPM logoJPM
IndustryFinancial - Capital MarketsMedical - Care FacilitiesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesBanks - Diversified
Market Cap$74M$871M$95M$3.82B$25.15B$931.59B
Revenue (TTM)$4M$238M$107M$645M$3.32B$280.33B
Net Income (TTM)$-290M$1M$7M$196M$942M$57.05B
Gross Margin-376.0%42.2%69.0%89.1%75.0%60.0%
Operating Margin-82.2%-1.2%13.6%33.3%28.8%25.9%
Forward P/E37.0x5.4x14.3x17.1x15.0x
Total Debt$210M$0.00$26M$10M$96M$942.38B
Cash & Equiv.$23M$37M$23M$219M$1.42B$343.34B

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NAKA
TALK
OPRX
DOCS
VEEV
JPM
StockMay 24Jun 26Return
Nakamoto Inc. (NAKA)1003.5-96.5%
Talkspace, Inc. (TALK)100198.5+98.5%
OptimizeRx Corporat… (OPRX)10042.1-57.9%
Doximity, Inc. (DOCS)10073.7-26.3%
Veeva Systems Inc. (VEEV)10088.9-11.1%
JPMorgan Chase & Co. (JPM)100164.6+64.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TALK and DOCS are tied at the top with 2 categories each (6-stock set) — the right choice depends on your priorities. Doximity, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. OPRX, VEEV, and JPM also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
NAKA
Nakamoto Inc.
The Financial Services Pick

NAKA doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.

Best for: financial services exposure
TALK
Talkspace, Inc.
The Defensive Pick

TALK has the current edge in this matchup, primarily because of its strength in defensive.

  • Beta 0.73, current ratio 6.38x
  • 22.0% revenue growth vs NAKA's -33.0%
  • +82.5% vs NAKA's -99.3%
Best for: defensive
OPRX
OptimizeRx Corporation
The Growth Play

OPRX ranks third and is worth considering specifically for growth exposure.

  • Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
  • Lower P/E (5.4x vs 15.0x)
Best for: growth exposure
DOCS
Doximity, Inc.
The Value Pick

DOCS is the #2 pick in this set and the best alternative if valuation efficiency is your priority.

  • PEG 0.27 vs VEEV's 0.94
  • 30.4% margin vs NAKA's -74.0%
  • 16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1%
Best for: valuation efficiency
VEEV
Veeva Systems Inc.
The Defensive Pick

VEEV is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.69, Low D/E 1.3%, current ratio 4.89x
  • Beta 0.69 vs NAKA's 2.88, lower leverage
Best for: sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 15 yrs, beta 0.94, yield 1.8%
  • 495.3% 10Y total return vs VEEV's 360.3%
  • 1.8% yield; 15-year raise streak; the other 5 pay no meaningful dividend
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTALK logoTALK22.0% revenue growth vs NAKA's -33.0%
ValueOPRX logoOPRXLower P/E (5.4x vs 15.0x)
Quality / MarginsDOCS logoDOCS30.4% margin vs NAKA's -74.0%
Stability / SafetyVEEV logoVEEVBeta 0.69 vs NAKA's 2.88, lower leverage
DividendsJPM logoJPM1.8% yield; 15-year raise streak; the other 5 pay no meaningful dividend
Momentum (1Y)TALK logoTALK+82.5% vs NAKA's -99.3%
Efficiency (ROA)DOCS logoDOCS16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1%

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NAKANakamoto Inc.
FY 2025
Product Retail Sales
100.0%$1,479
TALKTalkspace, Inc.

Segment breakdown not available.

OPRXOptimizeRx Corporation
FY 2025
Other Revenue
100.0%$215,000
DOCSDoximity, Inc.
FY 2026
Subscription
94.3%$608M
Service, Other
5.7%$36M
VEEVVeeva Systems Inc.
FY 2026
Subscription Services Veeva Commercial Cloud
86.9%$1.3B
Professional Services Veeva Commercial Cloud
13.1%$189M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDOCSLAGGINGVEEV

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 71519.7x NAKA's $4M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to NAKA's -74.0%. On growth, NAKA holds the edge at +3.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$4M$238M$107M$645M$3.3B$280.3B
EBITDAEarnings before interest/tax-$320M$2M$19M$227M$1.1B$81.4B
Net IncomeAfter-tax profit-$290M$1M$7M$196M$942M$57.0B
Free Cash FlowCash after capex-$46M-$6M$14M$215M$518M$100.9B
Gross MarginGross profit ÷ Revenue-3.8%+42.2%+69.0%+89.1%+75.0%+60.0%
Operating MarginEBIT ÷ Revenue-82.2%-1.2%+13.6%+33.3%+28.8%+25.9%
Net MarginNet income ÷ Revenue-74.0%+0.5%+6.4%+30.4%+28.4%+20.4%
FCF MarginFCF ÷ Revenue-11.7%-2.7%+13.4%+33.3%+15.6%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+3.6%+18.2%-9.5%+5.1%+16.3%
EPS Growth (YoY)Latest quarter vs prior year-88.4%+78.0%-67.7%+14.6%+16.0%
DOCS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

OPRX leads this category, winning 4 of 7 comparable metrics.

At 16.6x trailing earnings, JPM trades at a 87% valuation discount to TALK's 130.0x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.40x vs VEEV's 1.57x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$74M$871M$95M$3.8B$25.2B$931.6B
Enterprise ValueMkt cap + debt − cash$261M$834M$98M$3.6B$23.8B$1.53T
Trailing P/EPrice ÷ TTM EPS-0.41x130.00x18.81x20.87x28.47x16.63x
Forward P/EPrice ÷ next-FY EPS est.36.96x5.39x14.27x17.09x14.98x
PEG RatioP/E ÷ EPS growth rate0.40x1.57x0.94x
EV / EBITDAEnterprise value multiple138.33x5.98x16.82x19.95x18.80x
Price / SalesMarket cap ÷ Revenue40.51x3.81x0.87x5.93x7.87x3.33x
Price / BookPrice ÷ Book value/share0.09x7.72x0.75x4.28x3.58x2.57x
Price / FCFMarket cap ÷ FCF5.11x18.15x9.24x
OPRX leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 5 of 9 comparable metrics.

DOCS delivers a 19.4% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-85 for NAKA. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), OPRX scores 7/9 vs NAKA's 2/9, reflecting strong financial health.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-84.8%+1.0%+5.5%+19.4%+13.4%+15.9%
ROA (TTM)Return on assets-56.5%+0.9%+4.0%+16.5%+11.0%+1.3%
ROICReturn on invested capital-42.1%+3.9%+6.8%+19.8%+12.9%+4.5%
ROCEReturn on capital employed-76.2%+2.7%+7.8%+20.7%+13.8%+8.9%
Piotroski ScoreFundamental quality 0–9267665
Debt / EquityFinancial leverage0.41x0.20x0.01x0.01x2.60x
Net DebtTotal debt minus cash$187M-$37M$3M-$209M-$1.3B$599.0B
Cash & Equiv.Liquid assets$23M$37M$23M$219M$1.4B$343.3B
Total DebtShort + long-term debt$210M$0$26M$10M$96M$942.4B
Interest CoverageEBIT ÷ Interest expense-24.72x1.89x2.84x0.74x
DOCS leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TALK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $23,495 today (with dividends reinvested), compared to $351 for NAKA. Over the past 12 months, TALK leads with a +82.5% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors TALK at 62.1% vs NAKA's -67.3% — a key indicator of consistent wealth creation.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-74.0%+48.1%-59.1%-52.8%-29.5%+3.4%
1-Year ReturnPast 12 months-99.3%+82.5%-62.1%-65.0%-45.1%+25.9%
3-Year ReturnCumulative with dividends-96.5%+326.2%-65.6%-35.5%-23.5%+144.6%
5-Year ReturnCumulative with dividends-96.5%-42.2%-90.5%-61.4%-49.3%+135.0%
10-Year ReturnCumulative with dividends-96.5%-48.5%+56.8%-61.4%+360.3%+495.3%
CAGR (3Y)Annualised 3-year return-67.3%+62.1%-29.9%-13.6%-8.5%+34.7%
TALK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TALK and VEEV each lead in 1 of 2 comparable metrics.

VEEV is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.4% from its 52-week high vs NAKA's 0.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5002.88x0.73x2.18x0.75x0.69x0.94x
52-Week HighHighest price in past year$679.20$5.23$22.25$76.51$310.50$337.77
52-Week LowLowest price in past year$0.38$2.22$4.57$17.16$148.05$267.80
% of 52W HighCurrent price vs 52-week peak+0.6%+99.4%+22.8%+26.7%+49.9%+98.7%
RSI (14)Momentum oscillator 0–10037.451.647.347.446.470.9
Avg Volume (50D)Average daily shares traded281K1.5M436K3.9M2.3M7.2M
Evenly matched — TALK and VEEV each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NAKA as "Buy", TALK as "Hold", OPRX as "Buy", DOCS as "Hold", VEEV as "Buy", JPM as "Buy". Consensus price targets imply 234.6% upside for OPRX (target: $17) vs 1.0% for TALK (target: $5). JPM is the only dividend payer here at 1.78% yield — a key consideration for income-focused portfolios.

MetricNAKA logoNAKANakamoto Inc.TALK logoTALKTalkspace, Inc.OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.VEEV logoVEEVVeeva Systems Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyHoldBuyHoldBuyBuy
Price TargetConsensus 12-month target$8.00$5.25$17.00$29.47$235.38$339.75
# AnalystsCovering analysts21015234361
Dividend YieldAnnual dividend ÷ price+1.8%
Dividend StreakConsecutive years of raises01015
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap+0.4%+2.0%0.0%+11.3%+0.7%+3.7%
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway

DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OPRX leads in 1 (Valuation Metrics). 1 tied.

Best OverallDoximity, Inc. (DOCS)Leads 2 of 6 categories
Loading custom metrics...

NAKA vs TALK vs OPRX vs DOCS vs VEEV vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NAKA or TALK or OPRX or DOCS or VEEV or JPM a better buy right now?

For growth investors, Talkspace, Inc.

(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 6x trailing P/E (15. 0x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NAKA or TALK or OPRX or DOCS or VEEV or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 6x versus Talkspace, Inc. at 130. 0x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus Veeva Systems Inc. 's 0. 94x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — NAKA or TALK or OPRX or DOCS or VEEV or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 0%, compared to -96. 5% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: JPM returned +495. 3% versus NAKA's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NAKA or TALK or OPRX or DOCS or VEEV or JPM?

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 69β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately 321% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NAKA or TALK or OPRX or DOCS or VEEV or JPM?

By revenue growth (latest reported year), Talkspace, Inc.

(TALK) is pulling ahead at 22. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NAKA or TALK or OPRX or DOCS or VEEV or JPM?

Doximity, Inc.

(DOCS) is the more profitable company, earning 30. 4% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NAKA or TALK or OPRX or DOCS or VEEV or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus Veeva Systems Inc. 's 0. 94x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5. 4x forward P/E versus 37. 0x for Talkspace, Inc. — 31. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 234. 6% to $17. 00.

08

Which pays a better dividend — NAKA or TALK or OPRX or DOCS or VEEV or JPM?

In this comparison, JPM (1.

8% yield) pays a dividend. NAKA, TALK, OPRX, DOCS, VEEV do not pay a meaningful dividend and should not be held primarily for income.

09

Is NAKA or TALK or OPRX or DOCS or VEEV or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 8% yield, +495. 3% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +495. 3%, NAKA: -96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NAKA and TALK and OPRX and DOCS and VEEV and JPM?

These companies operate in different sectors (NAKA (Financial Services) and TALK (Healthcare) and OPRX (Healthcare) and DOCS (Healthcare) and VEEV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; TALK is a small-cap high-growth stock; OPRX is a small-cap high-growth stock; DOCS is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while NAKA, TALK, OPRX, DOCS, VEEV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.